Genespire is focused on advancing gene therapy, particularly for children suffering from genetic disorders. The company specializes in the development of immune-shielded lentiviral vectors, which are designed to deliver therapeutic genes effectively while minimizing the immune response. This innovative approach aims to enhance the safety and efficacy of gene therapies, making them more accessible to patients in need of potentially life-saving treatments.

The mission of Genespire underscores its commitment to providing cutting-edge solutions in the field of gene therapy. By leveraging advanced technologies, the company seeks to transform the landscape of treatment for genetic diseases, ensuring that affected children have access to therapies that can significantly improve their quality of life. Through ongoing research and development, Genespire aims to build a future where gene therapy is a viable option for those battling genetic conditions.

Italy

Genespire is a biotechnology company focused on the development of durable and transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners.

Genespire

Company Details